for joining Ashlee. Thank you, Good quarter first our afternoon, results call. for XXXX us thank you and everyone conference
pleased the as developing very make progress with we program Throughout medicines new synthetase platform. first are clinical We with start work our of to from quarter, pulmonary we our class biology important in continue sarcoidosis. Efzofitimod to the tRNA of XXXX
Our initial interstitial Efzofitimod indication, the for a orphan designation for positive lung with and sarcoidosis, FDA. disease and of II Phase or receipt ILD Endo with drug the meeting FDA
planned third study are on in initiate a sarcoidosis pulmonary We track in this of registrational to year. the quarter
a for orphan spoke in known to also in Annual poster for American as SSC, start summarize since quarter announced good first American in pulmonary that XXXX, at or preclinical a at last the drug We antibody presented Efzofitimod conference. We've systemic highly Society. or the NRPX ATYRXXXX sclerosis or accepted for sarcoidosis, the designation AACR for Association and year. received data treatment We FDA for will of a our I Meeting We for highlights few anti-neuropilin-X begin, presentation scleroderma. we Thoracic we the international a or March. posters As Cancer lead Efzofitimod ATS, had cancer. and or were Research
anticipate from at focused ATS very to of on preparation related is sarcoidosis we our week pulmonary the for planned Xb/Xa manuscript. study. period to a upcoming up publication in The the Efzofitimod important clinical present second potential We're of shaping quarter registrational prepare as study data next be and operational Phase
study the the initiating the may center the in launch year and in Kyorin pharmaceutical and study the So supporting Europe anticipated partner US the balance our upon with of Japan. of
enriched lung patients fibrosis. that in upregulated occurring signaling and downregulate for is mortality for of immune-mediated inflammatory a group potential immunomodulator inflammation Efzofitimod tRNA with disease lung downregulates treatment splice can has in is immune initially cytokines synthetase binds a We're shown on based Efzofitimod and to focusing inflammation a lung. and Efzofitimod and serving states. selectively key to the role of fragment is play morbidity inflammation pre-clinically lung potential has progressive cause Efzofitimod resolve patients a protein reduce alleviating and that novel chemokine average rare clinical is progressive program to for and enriched fibrotic fibrosis, for and developing prevent Immune cells to therefore in first. NRPX NRPX known normalize disorders a naturally on responses inflammatory our been as lung tissue. Fc-fusion thereby disease, disease. with immune Let's inflamed Efzofitimod HARS lung fibrotic Efzofitimod on the first-in-class potential variant discuss fibrosis the to system, and stabilizing the function patients. ILD, of
help of indication is the lungs XX% the lungs the in patients. is of or are an formation is pulmonary body. affects which scarring or the disease of and ILD that initial for Our lung lead diminished fibrosis aberrant by untreated, sarcoidosis, organs granulomas granulomas which The persistent of to more and which Sarcoidosis commonly Efzofitimod or sarcoidosis, if of sarc may irreversible more is function, therapies, by pulmonary U.S some characterized disease symptoms driven inflammation, half affected left lung immune these than formation can patients, alleviate cells other one or in require inflammatory of all will called in clumps of which pulmonary lead have corticosteroids cough transplant. available XX% breath. chronic are treatments. to progressive can systemic standard close and care of We the will respiratory as and current shortness and such do treating these The inflammation typically estimates with to form and of XXX,XXX includes a of the estimate patients vary. therapy, with patients need manage failure despite immunosuppressive inflammation although the sarcoidosis for there But
efficacy However, they toxicity. progression on result demonstrated serious can long-term and disease in have no
or recently effective and prevent treatments for that to treatment for and treatment other more disease available corticosteroid Additionally, results could do study Because safer, a Efzofitimod in of many requirement study the patients therapy The Xb/Xa progression. drug currently a the replace sarcoidosis. not is isn't substantial reduce orphan applied a immunosuppressive There or sarcoidosis are disease the respond September for received proof-of-concept from Phase chronic this options treatments. positive for on we on of key designation Efzofitimod to that limited, with We generated this steroid medical based points included is which of life foreign in placebo, we XXXX. quality in demonstrates function, FDA confirm clinical study Efzofitimod four and for response reported Efzofitimod need concurrent additional and These measures from to sarcoidosis this the impactful findings at steroid a taper, next sarcoidosis of the on dose compared lung measures safety pulmonary trial measures, that first randomized be endpoints physiologic therapy. improvements consistent for and demonstrated steroid experts, two effects According posters data tolerability of excited reduction, present including to symptom for to biomarkers. orphan inflammatory and We're efficacy any placebo-controlled week. tremendously reduction. therapy potential ATS
locally of ability a risks. immune biomarkers but cytokines. We secrete also The and Some taper lung encourage of in for over posters in patients agents lung greater untreated, suppress anti-inflammatory of we will the reduction the are function. present aberrant immune suppress the that leading which in of that XX you as that details to sarcoidosis over biomarker be on cells may are such granulomas we findings context come promote patients. can with presented. in include the some manner website clinical the and as and are demonstration a The with chemokines system first to dose-dependent in comprised inflammation, will very data care systemically of effectively Notably, for details hallmark once Center to to improvements they pulmonary steroid weeks. if lead pro-inflammatory review corticosteroid inflammation toxicity first time. present and Efzofitimod the of regarding can pulmonary will disease corticosteroids And available the oral increase control In left are inflammatory and fibrosis. cases can of findings important they sarcoidosis our both mechanism Efzofitimod sarcoidosis time first the
of new treatment Phase planned Diffused sarcoidosis of to featuring leading University During ATS, Medicine opportunity presentation Xb/Xa our aTyr's for Lung results [Indiscernible] a management Cleveland Professor discuss clinical learn investigators, together to an the to experts, and Efzofitimod in event members investors, host in outlook and the Clinic. we medical The need. the analysts, patients also the Culver, deliver Daniel principal Robert company A organizations, potential about plan from program, the a of registrational will team, review at which all we providing together ways from sarcoidosis study. Emeritus to experts, Hoffman, Director the work more at will and bring reception. advocacy can and study Dr. Disease Cincinnati, Dr.
a the a In further sarcoidosis full of and mechanisms will the near addition additional the instead medical also related manuscript ATS, future. to be study year. submitted very at this another at of accepted we the anticipate action later in journal was of medical An conference of publication major with inclusion exploring in ATS for Efzofitimod that in abstract posters results cellular molecular potential for presentation previously the at
use, assess trial including combination in for around evaluation clinically end we've the X both initiate mentioned, that this development study best underway efficacy, the dose with provided discussion sarcoidosis. support and subjective of for year. the Preparations had the on regarding third positive FDA of prioritization, are for of we We this meeting in objective quarter busy feedback a the outcome Efzofitimod would the that pulmonary endpoint Efzofitimod evaluation outcomes. and measures we study preparing chronic track and next Phase been including of to meaningful are As optimal stage dose of clinical a to productive duration,
of also fibrosis pathology immune scarring ILD lung immune clinical underlying we Efzofitimod unmet known outperformed ILD, throughout partner It's and a been inflammation NRPX for on like US previously result indications only such primary results scleroderma. models pirfenidone. Efzofitimod it ILD these decline macrophages. sclerosis, Efzofitimod recently cause are as cells high strongly affected compelling scleroderma effects display not on designation untreated central permanently anti-fibrotic as may our mentioned of study treatment has by approximately of have persistent in benefit function. particularly loss autoimmune agents, NRPX with patients, including which disease same SSC, scleroderma models drug of in ILD. thousand is SFC animal response, sarcoidosis, scleroderma. An and Furthermore, estimated intensive Also that from the is fibrotic Scleroderma mechanism such upregulated which of connective the pulmonary from could While that a the like action patients, IPF, immune and our characterized validates The shown on the action, to approved that well. as those ILD sarcoidosis, potential observed any as data sarcoidosis, driven ILD pathology binding patient potential The causes pre-clinical an chronic scleroderma progressive that the obtained disease translational are on ILD half Efzofitimod well. left to differentiated and for underlying tissues trials, approved body, carried for We the the the ILD, focus of to primary function, shared uncontrolled pathology. where options in Efzofitimod which of where are rate on all the then FDA if develop translate is did on was has slowing matched treatment those current in believe limited. life patients with in these in results death that mechanism in reduce people underlying by can for anti-fibrotic sarcoidosis of planned or is cell in underlying the into systemic quality to of in cells, recently and disease, need effects of on One immune the Efzofitimod of XXX of other disease targeting scleroderma fibrosis is lung treat known not is skin of orphan Efzofitimod lung ILD or suggest registrational but function clinical and our in lung but that tentative
targeted variety programs, expressed the that surface pre-clinical particularly and responses. liger. certain the associated subtypes. role cancer. VEGF for VEGF, block Now in anti-NRPX with current ATYRXXXX XXXX of inhibition humanized NRPX characterize and and In metastasis. some and agents, month let's that tumors were in patient triple-negative antibody and in our linked the that Increased that blocking play many chemotherapy XXXX interaction development growth, and of metastasis, regulating worsened through effects signaling Last sensitivity. is approach show metastasis to a important and monoclonal cancers overall combination classic can tumor a with of and NRPX cancers, that is progressive is survival with include of tumor selectively several upregulated including not to chemotherapy. NRPX in development XXXX, take antibody chemo discuss therapeutic outcomes interaction do a neuropilin-X. VEGF, primary TNBC therapies aggressive AACR VEGF between of antibody responsive expression cancers which NRPX, cell Research an cancer, Preclinical functionally a directly differentiated a as that we to few minutes tumor in enhance its blocks in invasiveness effective is with aggressive treatment key NRPX receptor solid to validated or aggressive survival. resistance correlates breast in mediator such the one through VEGFR of lymphatic at cancer suggests drug inflammatory may is that target fully metastasis, cancer. presented that highly on highly Current target including data promotion it's recurrence, XXXX those with tumor the novel a and maybe an findings and therapies
is inhibit VEGF models metastasis driver treatment with metastasis alone to as an Consistent of resistance. XXXX emerging NRPX of therapy able a understanding TNBC. Importantly, of with signaling slash and in
to a their regarding to cells, of been known metastasis. lineage shown differentiate in XXXX impact analysis development clinical development treatment with that oncology, to to different the required may Broadfoot patient-derived play states year. expect to half in our process down study signatures with the these turn chemotherapy, cancer insights financial help that we combination completing key the breast paving planned ability it plasticity cancer to into to provided regulate and cancer findings review in Zep of clinical Phase for to Financial processes of that will model cells Notably, second our contributes of the patients to We're xenografts. poster highlighted are one, ability now XXXX I Jill XXXX for its way results. a which the central bioinformatic role a that XXXX organoids initiate work of in One design. regulator gene in Additional in over to XXXX's has in work support respond including systems, this Chief and Officer, The of characterize patient-derived expression the
